EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte Studie

Neoadjuvant nab-paclitaxel plus gemcitabine followed by modified FOLFIRINOX for resectable pancreatic cancer: A randomized phase 3 trial

Xueli Bai, Xiang Li, Yiwen Chen, Guoliang Qiao, Qi Zhang, Tao Ma, Shunliang Gao, Min Zhang, Yan Shen, Jian Wu, Jun Yu, Risheng Que und 5 weitere

Cancer Cell · 2025-12 · 43 (12) · 2259-2267.e2

DOI: 10.1016/j.ccell.2025.09.009 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Cancer Cell, 2025-12. Verfasst von Xueli Bai und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China; Innovat…. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Deoxycytidine, Albumins. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Science and Technology Department of Zhejiang Province, Key Research and Development Program of Zhejiang Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This single-center, randomized phase 3 trial (NCT03750669) evaluated sequential neoadjuvant nab-paclitaxel plus gemcitabine followed by modified FOLFIRINOX versus upfront surgery in 324 patients with resectable pancreatic cancer. Patients in the neoadjuvant group received nab-paclitaxel plus gemcitabine followed by modified FOLFIRINOX before surgery and then four cycles of adjuvant therapy (preferably gemcitabine plus capecitabine), while those in the upfront surgery group underwent immediate resection followed by six cycles of adjuvant therapy. The primary endpoint was event-free survival. Notably, 50% of patients had tumors in the pancreatic body or tail. Median event-free survival was 15.3 months (95% confidence interval [CI], 12.6-19.3) versus 10.9 months (95% CI, 9.1-13.5; hazard ratio [HR], 0.71; 95% CI, 0.54-0.93; p = 0.0136). Median overall survival was 35.4 months versus 27.2 months (HR, 0.73; 95% CI, 0.53-1.00; nominal p = 0.0477). Grade ≥3 adverse events occurred in 47.6% versus 30.7% of patients. This neoadjuvant regimen improves event-free survival with manageable safety.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsDeoxycytidineAlbuminsPaclitaxelNeoadjuvant TherapyHumansGemcitabineFemaleMaleMiddle AgedAgedFluorouracilLeucovorinOxaliplatinIrinotecanAdult

Stichwörter der Autor:innen

FOLFIRINOXnab-paclitaxelneoadjuvant therapyrandomized controlled trialresectable pancreatic cancer

Substanzen

GemcitabineDeoxycytidine130-nm albumin-bound paclitaxelAlbuminsPaclitaxelFluorouracilLeucovorinOxaliplatinfolfirinoxIrinotecan

Autor:innen und Institutionen

  • Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China; Innovation Center for the Study of Pancreatic Diseases of Zhejiang Province,…
  • Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Department of Pathology, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Department of Radiology, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Department of Ultrasound, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.

Förderung

  • National Natural Science Foundation of China
  • Science and Technology Department of Zhejiang Province
  • Key Research and Development Program of Zhejiang Province
  • Natural Science Foundation of Jiangxi Province
  • National Key Research and Development Program of China

Zitieren

APA

Bai, X., Li, X., Chen, Y., Qiao, G., Zhang, Q., Ma, T., Gao, S., Zhang, M., Shen, Y., Wu, J., Yu, J., Que, R., Zhang, X., Sun, K., Xiao, W., Jiang, T., & Liang, T. (2025). Neoadjuvant nab-paclitaxel plus gemcitabine followed by modified FOLFIRINOX for resectable pancreatic cancer: A randomized phase 3 trial. Cancer Cell, 43(12), 2259-2267.e2. https://doi.org/10.1016/j.ccell.2025.09.009

Vancouver

Bai X, Li X, Chen Y, Qiao G, Zhang Q, Ma T, et al. Neoadjuvant nab-paclitaxel plus gemcitabine followed by modified FOLFIRINOX for resectable pancreatic cancer: A randomized phase 3 trial. Cancer Cell. 2025;43(12):2259-2267.e2. doi:10.1016/j.ccell.2025.09.009

BibTeX
@article{Bai2025,
  author = {Bai, Xueli and Li, Xiang and Chen, Yiwen and Qiao, Guoliang and Zhang, Qi and Ma, Tao and Gao, Shunliang and Zhang, Min and Shen, Yan and Wu, Jian and Yu, Jun and Que, Risheng and Zhang, Xiaochen and Sun, Ke and Xiao, Wenbo and Jiang, Tian'an and Liang, Tingbo},
  title = {Neoadjuvant nab-paclitaxel plus gemcitabine followed by modified FOLFIRINOX for resectable pancreatic cancer: A randomized phase 3 trial},
  journal = {Cancer Cell},
  year = {2025},
  volume = {43},
  number = {12},
  pages = {2259--2267.e2},
  doi = {10.1016/j.ccell.2025.09.009}
}
Kostenlos starten →